Intermittent Theta Burst Stimulation for ADHD
(WINK Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how a brain stimulation treatment, intermittent theta burst stimulation (iTBS), might alleviate ADHD symptoms by targeting working memory and inhibitory control. Researchers are testing two different brain areas to determine which is more effective in enhancing these skills. The trial seeks adolescents with ADHD who have parent-reported issues with memory and self-control. Participants should have experienced these challenges for some time and meet specific ADHD diagnosis criteria. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research on ADHD treatments.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes those on medications that lower the seizure threshold, except for psychostimulants if considered safe. It's best to discuss your specific medications with the trial team.
What prior data suggests that intermittent theta burst stimulation (iTBS) is safe for adolescents with ADHD?
Research has shown that intermittent theta burst stimulation (iTBS) is generally safe for children with ADHD. In one study, 165 young participants received iTBS, and researchers reported no serious side effects like seizures. Mild side effects occurred in 10.5% of cases, but these were not severe and did not require stopping the treatment.
Another study on iTBS showed promising results for improving ADHD symptoms without major safety concerns. Although this treatment is not yet approved for ADHD, these findings suggest it is well-tolerated. It is important to consult a healthcare provider to discuss potential risks and benefits before joining a trial.12345Why are researchers excited about this trial?
Researchers are excited about Intermittent Theta Burst Stimulation (iTBS) for ADHD because it offers a new approach by using targeted brain stimulation. Unlike standard treatments like medication and behavioral therapy, iTBS involves non-invasive magnetic pulses to stimulate brain regions associated with attention and impulse control. This method has the potential to deliver quicker results and fewer side effects compared to traditional options. Additionally, with different stimulation targets, such as the left DLPFC and right pre-SMA, iTBS could provide tailored treatments based on individual patient needs.
What evidence suggests that this trial's treatments could be effective for ADHD?
This trial will compare two different applications of intermittent theta burst stimulation (iTBS) for treating ADHD in teenagers. Research has shown that iTBS, which involves repeated brain stimulation, may help treat ADHD. In one study, 75% of participants noticed an improvement in their ADHD symptoms after undergoing iTBS sessions twice a day for 10 days. Another study found that intensive iTBS sessions resulted in a 79% remission rate, significantly better than typical treatment outcomes. These findings suggest that iTBS might improve issues like working memory and self-control in teens with ADHD. Although more research is needed, the early results are promising for those considering this treatment.12467
Are You a Good Fit for This Trial?
This trial is for adolescents aged 12-18 with ADHD, specifically those who have working memory and inhibitory control deficits as reported by parents. Participants must be diagnosed with ADHD to qualify.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 3x-daily iTBS targeting either the left DLPFC or right PreSMA for a total of ten days (30 total sessions)
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Intermittent Theta Burst Stimulation (iTBS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bradley Hospital
Lead Sponsor